Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (201-210 of 791) with videos related to

Pageof 80
Sort By:
Blood|November 15, 2013
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutantsAllison Galanis, Hayley Ma, Trivikram Rajkhowa, et al.
Cancer|March 15, 2008
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulationsTai-Sung Lee, Steven J Potts, Hagop Kantarjian, et al.
Revista Brasileira De Hematologia E Hemoterapia|October 11, 2012
The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor eraIlana Zalcberg Renault, Vanesa Scholl, Rocio Hassan, et al.
Cancer Causes & Control : CCC|May 26, 2026
Multilevel insights into obesity, race/ethnicity, and survival in early-onset colorectal cancer in GeorgiaMeng-Han Tsai, Marlo Vernon, Malcolm Bevel, et al.
Cancer|July 25, 2003
Chronic myelogenous leukemia: a review and update of therapeutic strategiesGuillermo Garcia-Manero, Stefan Faderl, Susan O'Brien, et al.
American Journal of Cancer Research|February 7, 2024
Temporal trends in early-onset colorectal cancer incidence (2000-2020) by age group and five geographic regions in the state of GeorgiaMeng-Han Tsai, Justin X Moore, Daramola N Cabral, et al.
Journal of Hematology|February 12, 2025
Allogeneic Stem Cell Transplantation for High/Ultra High-Risk Multiple MyelomaCharles Weeks, Rohan Vuppala, Matthew Gold, et al.
Blood|May 31, 2011
Comparison of thalidomide and lenalidomide as therapy for myelofibrosisElias Jabbour, Deborah Thomas, Hagop Kantarjian, et al.
Cancer|October 6, 2010
Experimental therapeutics for patients with myeloproliferative neoplasiasMeetu Agrawal, Ravin J Garg, Jorge Cortes, et al.
Cancer|January 16, 2007
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaAhmed Aribi, Gautam Borthakur, Farhad Ravandi, et al.
Pageof 80

Showing results (201-210 of 791) with videos related to

Sort By:
Pageof 80
Blood|November 15, 2013
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutantsAllison Galanis, Hayley Ma, Trivikram Rajkhowa, et al.
Cancer|March 15, 2008
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulationsTai-Sung Lee, Steven J Potts, Hagop Kantarjian, et al.
Revista Brasileira De Hematologia E Hemoterapia|October 11, 2012
The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor eraIlana Zalcberg Renault, Vanesa Scholl, Rocio Hassan, et al.
Cancer Causes & Control : CCC|May 26, 2026
Multilevel insights into obesity, race/ethnicity, and survival in early-onset colorectal cancer in GeorgiaMeng-Han Tsai, Marlo Vernon, Malcolm Bevel, et al.
Cancer|July 25, 2003
Chronic myelogenous leukemia: a review and update of therapeutic strategiesGuillermo Garcia-Manero, Stefan Faderl, Susan O'Brien, et al.
American Journal of Cancer Research|February 7, 2024
Temporal trends in early-onset colorectal cancer incidence (2000-2020) by age group and five geographic regions in the state of GeorgiaMeng-Han Tsai, Justin X Moore, Daramola N Cabral, et al.
Journal of Hematology|February 12, 2025
Allogeneic Stem Cell Transplantation for High/Ultra High-Risk Multiple MyelomaCharles Weeks, Rohan Vuppala, Matthew Gold, et al.
Blood|May 31, 2011
Comparison of thalidomide and lenalidomide as therapy for myelofibrosisElias Jabbour, Deborah Thomas, Hagop Kantarjian, et al.
Cancer|October 6, 2010
Experimental therapeutics for patients with myeloproliferative neoplasiasMeetu Agrawal, Ravin J Garg, Jorge Cortes, et al.
Cancer|January 16, 2007
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaAhmed Aribi, Gautam Borthakur, Farhad Ravandi, et al.
Pageof 80